Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Afexa rides flu concerns to record Q1: The maker of Cold-FX reports record revenue of $27.7 million (Canadian $29.5 million at Feb. 11 exchange rates), a 49.7 percent increase, during the quarter ended Dec. 31. Net earnings were also up substantially - 142.9 percent to $6.4 million - in Afexa Life Sciences' fiscal 2010 first quarter. Jack Moffatt, CEO of the Edmonton, Alberta, company, attributed increased sales of Cold-FX to public flu concerns, though "we expect demand to moderate in the second quarter" as cold and flu incidences are below the three-year average. Afexa said Feb. 11 it hopes the Olympics bring added exposure to its products, as Cold-FX is the official cold and flu remedy of the Winter Games. Immunity-FX launched in late 2009 and is awaiting a Natural Product Number from Health Canada (1"The Tan Sheet" Nov. 30, 2009). Afexa plans to expand Immunity-FX into all retail channels in which Cold-FX currently sells
You may also be interested in...
Sales & Earnings In Brief
Sanofi seeks more acquisitions: Sanofi-Aventis continues to "hunt" for bolt-on acquisitions to further diversify its portfolio and feed its pipeline now that it has "properly bedded down and integrated" Chattem, said CEO Chris Viehbacher. He told analysts April 29 that the environment is "quite promising" for acquisitions and Sanofi is "aggressively pursuing external growth opportunities." The Chattem deal significantly boosted Sanofi's consumer health care business, which grew 42.5 percent to €499 million ($661.1 million) in the firm's fiscal 2010 first quarter, according to a same-day release (1"The Tan Sheet" March 15, 2010). Viehbacher lauded Chattem as a keystone in the company's future as a switch platform for the allergy medication Allegra. He noted Sanofi filed the paperwork with FDA for the switch in March; he expects the switch evaluation to take the same amount of time as other new product applications. Prescription sales for Allegra fell 27.1 percent in the quarter due to new competition from generics launched in the U.S. last November. Overall sales for the Paris-based firm grew 5.8 percent, according to the release
Sales & Earnings In Brief
Sanofi seeks more acquisitions: Sanofi-Aventis continues to "hunt" for bolt-on acquisitions to further diversify its portfolio and feed its pipeline now that it has "properly bedded down and integrated" Chattem, said CEO Chris Viehbacher. He told analysts April 29 that the environment is "quite promising" for acquisitions and Sanofi is "aggressively pursuing external growth opportunities." The Chattem deal significantly boosted Sanofi's consumer health care business, which grew 42.5 percent to €499 million ($661.1 million) in the firm's fiscal 2010 first quarter, according to a same-day release (1"The Tan Sheet" March 15, 2010). Viehbacher lauded Chattem as a keystone in the company's future as a switch platform for the allergy medication Allegra. He noted Sanofi filed the paperwork with FDA for the switch in March; he expects the switch evaluation to take the same amount of time as other new product applications. Prescription sales for Allegra fell 27.1 percent in the quarter due to new competition from generics launched in the U.S. last November. Overall sales for the Paris-based firm grew 5.8 percent, according to the release
Sales & Earnings In Brief
Sanofi seeks more acquisitions: Sanofi-Aventis continues to "hunt" for bolt-on acquisitions to further diversify its portfolio and feed its pipeline now that it has "properly bedded down and integrated" Chattem, said CEO Chris Viehbacher. He told analysts April 29 that the environment is "quite promising" for acquisitions and Sanofi is "aggressively pursuing external growth opportunities." The Chattem deal significantly boosted Sanofi's consumer health care business, which grew 42.5 percent to €499 million ($661.1 million) in the firm's fiscal 2010 first quarter, according to a same-day release (1"The Tan Sheet" March 15, 2010). Viehbacher lauded Chattem as a keystone in the company's future as a switch platform for the allergy medication Allegra. He noted Sanofi filed the paperwork with FDA for the switch in March; he expects the switch evaluation to take the same amount of time as other new product applications. Prescription sales for Allegra fell 27.1 percent in the quarter due to new competition from generics launched in the U.S. last November. Overall sales for the Paris-based firm grew 5.8 percent, according to the release